AnaptysBio will present at the J.P. Morgan Healthcare Conference on January 13, 2026, detailing its immunology therapeutics pipeline.
Quiver AI Summary
AnaptysBio, Inc., a clinical-stage biotechnology company specializing in immunology therapeutics, announced that CEO Daniel Faga will present at the upcoming J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will be accessible via a live webcast on the company's investor website, with a replay available for 30 days post-event. AnaptysBio's pipeline includes several key therapeutics focused on autoimmune and inflammatory diseases, such as rosnilimab for rheumatoid arthritis and ANB033 for celiac disease. The company is also strategically planning to separate its biopharma operations from its royalty assets by the end of 2026 to better align with investor interests.
Potential Positives
- AnaptysBio will present at the prestigious 44th Annual J.P. Morgan Healthcare Conference, providing visibility and credibility within the healthcare investment community.
- The company is advancing a promising pipeline of therapeutics for autoimmune and inflammatory diseases, including ongoing clinical trials for key products like rosnilimab and ANB033.
- The planned separation of biopharma operations from royalty assets by year-end 2026 may enhance strategic focus and allow investors to better align their portfolios with specific opportunities and objectives.
Potential Negatives
- Announcement of separation of biopharma operations from royalty assets might indicate potential operational challenges or a shift in strategy that could create uncertainty among investors.
- The presentation at the healthcare conference may not be well-received if the company fails to demonstrate significant advancements or results in its clinical trials, potentially impacting investor confidence.
- The reliance on multiple early-stage trials (Phase 1 and Phase 2b) suggests that the company may face risks associated with long-term viability and delayed product commercialization.
FAQ
When is AnaptysBio presenting at the J.P. Morgan Healthcare Conference?
AnaptysBio will present on Tuesday, Jan 13, 2026, at 4:30 PM PT / 7:30 PM ET.
How can I access the AnaptysBio presentation?
A live webcast of the presentation will be available on the investor section of the Anaptys website.
What is AnaptysBio focused on?
AnaptysBio is focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases.
What notable products are in AnaptysBio's pipeline?
Key products include rosnilimab for rheumatoid arthritis, ANB033 for celiac disease, and ANB101 in development trials.
What recent announcement has AnaptysBio made about its operations?
AnaptysBio plans to separate its biopharma operations from its royalty assets by year-end 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANAB Insider Trading Activity
$ANAB insiders have traded $ANAB stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $ANAB stock by insiders over the last 6 months:
- ERIC J LOUMEAU (CHIEF LEGAL OFFICER) has made 0 purchases and 6 sales selling 40,881 shares for an estimated $1,776,385.
- DENNIS MULROY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 3 sales selling 25,725 shares for an estimated $1,205,332.
- HOLLINGS RENTON has made 0 purchases and 2 sales selling 10,231 shares for an estimated $200,713.
- J. ANTHONY WARE sold 3,900 shares for an estimated $193,342
- PAUL F. LIZZUL (Chief Medical Officer) sold 1,500 shares for an estimated $75,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ANAB Hedge Fund Activity
We have seen 80 institutional investors add shares of $ANAB stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 2,549,432 shares (-72.0%) from their portfolio in Q3 2025, for an estimated $78,063,607
- MILLENNIUM MANAGEMENT LLC added 1,315,688 shares (+646.4%) to their portfolio in Q3 2025, for an estimated $40,286,366
- UBS GROUP AG removed 1,197,237 shares (-94.1%) from their portfolio in Q3 2025, for an estimated $36,659,396
- CITIGROUP INC removed 975,954 shares (-93.3%) from their portfolio in Q3 2025, for an estimated $29,883,711
- BANK OF AMERICA CORP /DE/ removed 949,558 shares (-88.2%) from their portfolio in Q3 2025, for an estimated $29,075,465
- ASSENAGON ASSET MANAGEMENT S.A. added 822,975 shares (+4852.7%) to their portfolio in Q3 2025, for an estimated $25,199,494
- SOFINNOVA INVESTMENTS, INC. removed 778,094 shares (-75.4%) from their portfolio in Q3 2025, for an estimated $23,825,238
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ANAB Analyst Ratings
Wall Street analysts have issued reports on $ANAB in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 12/11/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/24/2025
- Wedbush issued a "Outperform" rating on 11/24/2025
- Barclays issued a "Overweight" rating on 10/13/2025
- JP Morgan issued a "Overweight" rating on 07/24/2025
To track analyst ratings and price targets for $ANAB, check out Quiver Quantitative's $ANAB forecast page.
$ANAB Price Targets
Multiple analysts have issued price targets for $ANAB recently. We have seen 10 analysts offer price targets for $ANAB in the last 6 months, with a median target of $55.5.
Here are some recent targets:
- Etzer Darout from Barclays set a target price of $55.0 on 12/17/2025
- Alex Thompson from Stifel set a target price of $56.0 on 12/11/2025
- Martin Fan from Wedbush set a target price of $50.0 on 11/24/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $51.0 on 11/24/2025
- John Lee from Truist Securities set a target price of $36.0 on 11/10/2025
- Derek Archila from Wells Fargo set a target price of $81.0 on 11/05/2025
- Yatin Suneja from Guggenheim set a target price of $100.0 on 11/05/2025
Full Release
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET.
A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events . A replay of the webcast will be available for at least 30 days following the event.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company’s pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease with plans to expand development into an additional indication; and ANB101, a BDCA2 modulator, in a Phase 1a trial. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist ( Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn .
Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more here .
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
[email protected]
